SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
GA Poland, IG Ovsyannikova, RB Kennedy - The Lancet, 2020 - thelancet.com
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is
crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such …
crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such …
Prospects for a safe COVID-19 vaccine
BF Haynes, L Corey, P Fernandes, PB Gilbert… - Science translational …, 2020 - science.org
Rapid development of an efficacious vaccine against the viral pathogen severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease …
respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease …
A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice
SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with …
transmissibility of the virus and the high rate of morbidity and mortality associated with …
[HTML][HTML] Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses
Various vaccine strategies have been proposed in response to the global COVID-19
pandemic, each with unique strategies for eliciting immune responses. Here, we developed …
pandemic, each with unique strategies for eliciting immune responses. Here, we developed …
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
S Rauch, N Roth, K Schwendt, M Fotin-Mleczek… - npj Vaccines, 2021 - nature.com
Abstract mRNA technologies have recently proven clinical efficacy against coronavirus
disease 2019 and are among the most promising technologies to address the current …
disease 2019 and are among the most promising technologies to address the current …
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the
development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are …
development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are …
COVID-19 vaccine design: the Janus face of immune enhancement
Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines
identified cellular immunopathology and antibody-dependent enhancement as potential …
identified cellular immunopathology and antibody-dependent enhancement as potential …
Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?
P Tiberghien, X de Lamballerie, P Morel… - Vox …, 2020 - Wiley Online Library
Plasma provided by COVID‐19 convalescent patients may provide therapeutic relief as the
number of COVID‐19 cases escalates steeply worldwide. Prior findings in various viral …
number of COVID‐19 cases escalates steeply worldwide. Prior findings in various viral …
Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies
DO Ricke - Frontiers in immunology, 2021 - frontiersin.org
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-
like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease …
like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease …
Consensus summary report for CEPI/BC March 12–13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines
PH Lambert, DM Ambrosino, SR Andersen, RS Baric… - Vaccine, 2020 - Elsevier
A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe …
2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe …